Our Programs

Epigenetics Program

DRUG CANDIDATE

Pracinostat HDAC Inhibitor

INDICATION / COMBINATION

Acute Myeloid Leukemia

Newly diagnosed, ≥75 years or unfit
Azacitidine (Vidaza®)
Pre-Clinical
Phase I
Phase II
Phase III
 
INDICATION / COMBINATION

Myelodysplastic Syndrome

Intermediate-2 & high-risk
Azacitidine (Vidaza®)
Pre-Clinical
Phase I
Phase II
Phase III
 
INDICATION / COMBINATION

Myelofibrosis

Front line & relapsed/refractory
Ruxolitinib (Jakafi®)
Pre-Clinical
Phase I
Phase II
Phase III
 

Signaling Program

DRUG CANDIDATE

ME-401 PI3K Delta Inhibitor

INDICATION / COMBINATION

B-Cell Malignancies

Recurrent CLL or follicular NHL
Single Agent, Dose Escalation
Pre-Clinical
Phase I
Phase II
Phase III
 

Cancer Metabolism Program

DRUG CANDIDATE

ME-344 Mitochondrial Inhibitor

INDICATION / COMBINATION

HER2-Negative Breast

Bevacizumab (Avastin)
Pre-Clinical
Phase I
Phase II
Phase III